Saniona (SANION) Life Science Summit 2025 summary

Financial position and partnerships

• Maintains strong financial position with $70 million in cash and expects $17.5 million in milestones next year.

• Secured two major deals: $28 million upfront from Acadia (total $600 million+), $42 million upfront from Jazz (total $1 billion+), both with royalties.

• Over $70 million received in the last 12 months; $410 million in development milestones and $1.6 billion in commercial milestones possible.

• Partnerships with Acadia and Jazz validate the Iron Chain platform and provide funding for internal pipeline advancement.

Pipeline and clinical development

• SAN711 (Acadia) for essential tremor to start phase 2 in 2025; SAN2355 (Jazz) for epilepsy to start phase 1 in 2025.

• Three internal assets advancing: two for epilepsy, one for major depressive disorder; phase 1 studies planned for late 2025 and early 2027.

• SAN2219 targets treatment-resistant epilepsy with a $1 billion market potential; phase 1 in Q3 2026, proof of concept in 2028.

• SAN2668 for pediatric epilepsies and DEE, phase 1 in Q4 2025, proof of concept in 2028; shows superior efficacy and fewer side effects in preclinical models.

• SAN2465 for treatment-resistant depression, phase 1 in 2027, targets rapid onset and cognitive improvement.

Market potential and competitive landscape

• Internal assets address large markets: epilepsy ($1 billion), pediatric DEE ($400 million+), and depression ($1 billion+).

• SAN2668 aims for broad DEE label, similar to Longboard's approach before $2.6 billion acquisition.

• Competitive landscape in pediatric epilepsy includes Jazz and others; many severe indications with high unmet need.

• Compounds designed for improved efficacy and reduced side effects compared to current standards like benzodiazepines.